| The role of angiotensin-converting enzyme inhibitors in the treatment of hypertension. | |
| | |
MedLine Citation:
|
PMID: 11602083 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Angiotensin-converting enzyme (ACE) inhibitors continue to find new uses. The Heart Outcomes Prevention Evaluation study has demonstrated their wide application as a preventive measure for patients at high risk of cardiovascular disease, but the available clinical trials in hypertensive subjects do not so far suggest any clear superiority over conventional treatment. The available trials may have been underpowered to detect non-blood pressure-related benefits on smooth muscle growth, endothelial function, left ventricular hypertrophy, and plaque rupture, when used in relatively low-risk subjects with uncomplicated hypertension. Clinical trials have also shown that two or more drugs are needed to lower blood pressure even to 140/90. Few patients have uncomplicated hypertension, so the choice of their drugs will be powerfully influenced by their other clinical problems. Nevertheless, there is a strong case for an attack on the renin-angiotensin system. Whether this will be by ACE inhibition, angiotensin-II receptor blockade, or both, is the subject of current clinical trials. |
| | |
Authors:
|
P Sleight |
Related Documents
:
|
6280623 - Oral converting enzyme inhibitor in malignant hypertension. 1381773 - Antiarrhythmic effects of the angiotensin converting enzyme inhibitor perindoprilat in ... 17444193 - Interrelationship of waist circumference and subcutaneous fat with metabolic and blood ... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current cardiology reports Volume: 3 ISSN: 1523-3782 ISO Abbreviation: Curr Cardiol Rep Publication Date: 2001 Nov |
Date Detail:
|
Created Date: 2001-10-16 Completed Date: 2001-12-07 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100888969 Medline TA: Curr Cardiol Rep Country: United States |
Other Details:
|
Languages: eng Pagination: 511-8 Citation Subset: IM |
Affiliation:
|
Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, England. peter.sleight@attglobal.net |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin-Converting Enzyme Inhibitors
/
therapeutic use* Blood Pressure / drug effects Clinical Trials as Topic Humans Hypertension / drug therapy* Hypertrophy, Left Ventricular / drug therapy Randomized Controlled Trials as Topic |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Implications of recent heart failure trials for patients with hypertension.
Next Document: Impact of meta-analysis in clinical practice: the example of psychiatry